Silver Book Fact

A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s…  
  • Stopping the Progress of Parkinson’s Would Save >$440,000 per Person
     
  • Impact of Slowed Progression by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • Average Annual Direct Medical Costs Per Person with Parkinson’s Disease
     
  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050